Association Study of Candidate Gene Polymorphisms and Obesity in a Young Mexican-American Population from South Texas

Archives of Medical Research

Volumn 42, Issue 6, 2011, Pages 523-531

  Duran Gonzalez, Jorge ^a   Ortiz, Ixiu ^a   Gonzales, Enrique ^a   Ruiz, Nicole ^a   Ortiz, Manti ^a   Gonzalez, Arthur ^a   Sanchez, Edna K ^a   Curet, Eugenia ^a   Fisher Hoch, Susan ^a   Rentfro, Anne ^b   Qu, Huiqi ^a   Nair, Saraswathy ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TEXAS AT BROWNSVILLE   (United States)

Author keywords

Diabetes; Genetic association; Mexican American; Obesity; Polymorphism

Indexed keywords

GENOMIC DNA; GLUCOSE; TRIACYLGLYCEROL;

ADOLESCENT; ARTICLE; DIET RESTRICTION; DNA EXTRACTION; ETHNIC GROUP; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SCREENING; GENOTYPE; GLUCOSE BLOOD LEVEL; HEIGHT; HUMAN; LINKAGE ANALYSIS; MALE; MEXICAN AMERICAN; NORMAL HUMAN; OBESITY; PHENOTYPE; QUANTITATIVE TRAIT; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES; WAIST CIRCUMFERENCE; WEIGHT;

ADOLESCENT; DNA; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MEXICAN AMERICANS; OBESITY; POLYMORPHISM, SINGLE NUCLEOTIDE; TEXAS;

EID: 82855171037     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2011.10.010     Document Type: Article

References (71)

1. Kopelman P. Health risks associated with overweight and obesity. Obesity Rev 2007, 8:13-17.
2. Flegal K.M., Carroll M.D., Ogden C.L., et al. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010, 303:235-241.
3. Singh G.K., Kogan M.D., van Dyck P.C. Changes in state-specific childhood obesity and overweight prevalence in the United States from 2003 to 2007. Arch Pediatr Adol Med 2010, 164:598-607.
4. Fisher-Hoch S.P., Rentfro A.R., Salinas J.J., et al. Socioeconomic status and prevalence of obesity and diabetes in a Mexican American community, Cameron County, Texas, 2004-2007. Prev Chronic Dis 2010, 7:A53.
5. Lawrence J.M., Mayer-Davis E.J., Reynolds K., et al. Diabetes in Hispanic American youth: prevalence, incidence, demographics, and clinical characteristics: the SEARCH for Diabetes in Youth Study. Diabetes Care 2009, 32(suppl 2):S123-S132.
6. Duncan G.E. Prevalence of diabetes and impaired fasting glucose levels among US adolescents: National Health and Nutrition Examination Survey, 1999-2002. Arch Pediatr Adolesc Med 2006, 160:523-528.
7. Rentfro A.R., Nino J.C., Pones R.M., et al. Adiposity, biological markers of disease, and insulin resistance in Mexican American adolescents, 2004-2005. Prev Chronic Dis 2011, 8:A40.
8. Bayles B. Perceptions of childhood obesity on the Texas-Mexico border. Public Health Nursing 2010, 27:320-328.
9. Fawcett K.A., Barroso I. The genetics of obesity: FTO leads the way. Trends Genet 2010, 26:266-274.
10. Yang W.J., Kelly T., He J. Genetic epidemiology of obesity. Epidemiol Rev 2007, 29:49-61.
11. Taylor R.W., Jones I.E., Williams S.M., et al. Evaluation of waist circumference, waist-to-hip ratio, and the conicity index as screening tools for high trunk fat mass, as measured by dual-energy X-ray absorptiometry, in children aged 3-19 y. Am J Clin Nutr 2000, 72:490-495.
12. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. Am J Clin Nutr 1998, 68:899-917.
13. Keskin M., Kurtoglu S., Kendirci M., et al. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 2005, 115:e500-e503.
14. Purcell S., Cherny S.S., Sham P.C. Genetic power calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 2003, 19:149-150.
15. Rankinen T., Zuberi A., Chagnon Y.C., et al. The human obesity gene map: the 2005 update. Obesity 2006, 14:529-644.
16. Canizales-Quinteros S., Aguilar-Salinas C.A., Ortiz-Lopez M.G., et al. Association of PPARG2 Pro12Ala variant with larger body mass index in Mestizo and Amerindian populations of Mexico. Human Biol 2007, 79:111-119.
17. Cole S.A., Mitchell B.D., Hsueh W.C., et al. The Pro12Ala variant of peroxisome proliferator-activated receptor-gamma 2 (PPAR-gamma 2) is associated with measures of obesity in Mexican Americans. Int J Obesity 2000, 24:522-524.
18. Cruz C., Camarena B., Mejia J.M., et al. The dopamine D2 receptor gene TaqI A1 polymorphism and alcoholism in a Mexican population. Arch Med Res 1995, 26:421-426.
19. Hsueh W.C., Cole S.A., Shuldiner A.R., et al. Interactions between variants in the beta(3)-adrenergic receptor and peroxisome proliferator-activated receptor-gamma 2 genes and obesity. Diabetes Care 2001, 24:672-677.
20. Konishi T., Calvillo M., Leng A.S., et al. Polymorphisms of the dopamine D-2 receptor, serotonin transporter, and GABA(A) receptor beta(3) subunit genes and alcoholism in Mexican-Americans. Alcohol 2004, 32:45-52.
21. Richardson D.K., Schneider J., Fourcaudot M.J., et al. Association between variants in the genes for adiponectin and its receptors with insulin resistance syndrome (IRS)-related phenotypes in Mexican Americans. Diabetologia 2006, 49:2317-2328.
22. Iizuka H., Awata T., Osaki M., et al. Promoter polymorphisms of the pigment epithelium-derived factor gene are associated with diabetic retinopathy. Biochem Biophys Res Commun 2007, 361:421-426.
23. Siitonen N., Pulkkinen L., Lindstrom J., et al. Association of ADIPOQ gene variants with body weight, type 2 diabetes and serum adiponectin concentrations: the Finnish Diabetes Prevention Study. BMC Med Genet 2011, 12:5.
24. Eiriksdottir G., Smith A.V., Aspelund T., et al. The interaction of adiposity with the CRP gene affects CRP levels: age, gene/environment susceptibilty-Reykjavik study. Int J Obes (Lond) 2009, 33:267-272.
25. Elbein S.C., Sun J., Scroggin E., et al. Role of common sequence variants in insulin secretion in familial type 2 diabetic kindreds: the sulfonylurea receptor, glucokinase, and hepatocyte nuclear factor 1alpha genes. Diabetes Care 2001, 24:472-478.
26. Nair S., Lee Y.H., Lindsay R.S., et al. 11 beta-Hydroxysteroid dehydrogenase Type 1: genetic polymorphisms are associated with type 2 diabetes in Pima Indians independently of obesity and expression in adipocyte and muscle. Diabetologia 2004, 47:1088-1095.
27. Blum K., Sheridan P.J., Wood R.C., et al. Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour. Pharmacogenetics 1995, 5:121-141.
28. Comings D.E., Flanagan S.D., Dietz G., et al. The dopamine D2 receptor (DRD2) as a major gene in obesity and height. Biochem Med Metab Biol 1993, 50:176-185.
29. Noble E.P., Noble R.E., Ritchie T., et al. D2 dopamine receptor gene and obesity. Int J Eat Disord 1994, 15:205-217.
30. Thomas G.N., Critchley J.A., Tomlinson B., et al. Relationships between the taqI polymorphism of the dopamine D2 receptor and blood pressure in hyperglycaemic and normoglycaemic Chinese subjects. Clin Endocrinol (Oxf) 2001, 55:605-611.
31. Lucht M., Samochowiec A., Samochowiec J., et al. Influence of DRD2 and ANKK1 genotypes on apomorphine-induced growth hormone (GH) response in alcohol-dependent patients. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:45-49.
32. Stice E., Spoor S., Bohon C., et al. Relation between obesity and blunted striatal response to food is moderated by TaqIA A1 allele. Science 2008, 322:449-452.
33. Ritchie T., Noble E.P. Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics. Neurochem Res 2003, 28:73-82.
34. Jonsson E.G., Nothen M.M., Grunhage F., et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 1999, 4:290-296.
35. Blum K., Braverman E.R., Wood R.C., et al. Increased prevalence of the Taq I A1 allele of the dopamine receptor gene (DRD2) in obesity with comorbid substance use disorder: a preliminary report. Pharmacogenetics 1996, 6:297-305.
36. Davis C., Levitan R.D., Kaplan A.S., et al. Dopamine transporter gene (DAT1) associated with appetite suppression to methylphenidate in a case-control study of binge eating disorder. Neuropsychopharmacology 2007, 32:2199-2206.
37. Wang G.J., Volkow N.D., Logan J., et al. Brain dopamine and obesity. Lancet 2001, 357:354-357.
38. Neville M.J., Johnstone E.C., Walton R.T. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Human Mutat 2004, 23:540-545.
39. Jenkinson C.P., Hanson R., Cray K., et al. Association of dopamine D2 receptor polymorphisms Ser311Cys and TaqIA with obesity or type 2 diabetes mellitus in Pima Indians. Int J Obes Relat Metab Disord 2000, 24:1233-1238.
40. Southon A., Walder K., Sanigorski A.M., et al. The Taq IA and Ser311 Cys polymorphisms in the dopamine D2 receptor gene and obesity. Diabetes Nutr Metab 2003, 16:72-76.
41. Davis C., Levitan R.D., Kaplan A.S., et al. Reward sensitivity and the D2 dopamine receptor gene: a case-control study of binge eating disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:620-628.
42. Feldman B.J. Glucocorticoids influence on mesenchymal stem cells and implications for metabolic disease. Pediatr Res 2009, 65:249-251.
43. Lindsay R.S., Wake D.J., Nair S., et al. Subcutaneous adipose 11 beta-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J Clin Endocrinol Metab 2003, 88:2738-2744.
44. Staab C.A., Maser E. 11 beta-Hydroxysteroid dehydrogenase type 1 is an important regulator at the interface of obesity and inflammation. J Steroid Biochem Mol Biol 2010, 119:56-72.
45. Morgan S.A., Sherlock M., Gathercole L.L., et al. 11beta-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle. Diabetes 2009, 58:2506-2515.
46. Karlsson C., Jernas M., Olsson B., et al. Differences in associations between HSD11B1 gene expression and metabolic parameters in subjects with and without impaired glucose homeostasis. Diabetes Res Clin Practice 2010, 88:252-258.
47. Franks P.W., Knowler W.C., Nair S., et al. Interaction between an 11betaHSD1 gene variant and birth era modifies the risk of hypertension in Pima Indians. Hypertension 2004, 44:681-688.
48. Koska J., de Court, Wake D.J., et al. 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue and prospective changes in body weight and insulin resistance. Obesity 2006, 14:1515-1522.
49. Meng Y.X., Ford E.S., Li C.Y., et al. Association of C-reactive protein with surrogate measures of insulin resistance among nondiabetic US adults: findings from National Health and Nutrition Examination Survey 1999-2002. Clin Chem 2007, 53:2152-2159.
50. Gelaye B., Revilla L., Lopez T., et al. Association between insulin resistance and C-reactive protein among Peruvian adults. Diabetol Metab Syndr 2010, 2:30.
51. Marioni R.E., Deary I.J., Murray G.D., et al. Genetic variants associated with altered plasma levels of C-reactive protein are not associated with late-life cognitive ability in four Scottish samples. Behavior Genet 2010, 40:3-11.
52. Gouda H.N., Sagoo G.S., Harding A.H., et al. The association between the peroxisome proliferator-activated receptor-gamma 2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis. Am J Epidemiol 2010, 171:645-655.
53. Fornage M., Jacobs D.R., Steffes M.W., et al. Inverse effects of the PPAR(gamma)2 Pro12Ala polymorphism on measures of adiposity over 15 years in African Americans and whites. The CARDIA study. Metabolism 2005, 54:910-917.
54. Nelson T.L., Fingerlin T.E., Moss L., et al. The PPARgamma Pro12Ala polymorphism is not associated with body mass index or waist circumference among Hispanics from Colorado. Ann Nutr Metab 2007, 51:252-257.
55. Yen C.J., Beamer B.A., Negri C., et al. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 1997, 241:270-274.
56. Ben Ali S., Ben Yahia F., Sediri Y., et al. Gender-specific effect of Pro12A1a polymorphism in peroxisome proliferator-activated receptor gamma-2 gene on obesity risk and leptin levels in a Tunisian population. Clin Biochem 2009, 42:1642-1647.
57. Dedoussis G.V., Vidra N., Butler J., et al. Peroxisome proliferator-activated receptor-gamma (PPAR gamma) Pro12Ala polymorphism and risk for pediatric obesity. Clin Chem Lab Med 2009, 47:1047-1050.
58. Ghoussaini M., Meyre D., Lobbens S., et al. Implication of the Pro 12Ala polymorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French population. BMC Med Genet 2005, 22:6.
59. Johansson L.E., Danielsson P., Norgren S., et al. Interaction between PPARG Pro12Ala and ADIPOQ G276T concerning cholesterol levels in childhood obesity. Int J Pediatr Obesity 2009, 4:119-125.
60. Fumeron F., Aubert R., Siddiq A., et al. Adiponectin gene polymorphisms and adiponectin levels are independently associated with the development of hyperglycemia during a 3-year period-The Epidemiologic Data on the Insulin Resistance Syndrome prospective study. Diabetes 2004, 53:1150-1157.
61. Gu H.F., Abulaiti A., Ostenson C.G., et al. Single nucleotide polymorphisms in the proximal promoter region of the adiponectin (APM1) gene are associated with type 2 diabetes in Swedish Caucasians. Diabetes 2004, 53:S31-S35.
62. Koster J.C., Permutt M.A., Nichols C.G. Diabetes and insulin secretion-the ATP-sensitive K+ channel (K-ATP) connection. Diabetes 2005, 54:3065-3072.
63. Gloyn A.L., Weedon M.N., Owen K.R., et al. Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes 2003, 52:568-572.
64. Sakamoto Y., Inoue H., Keshavarz P., et al. SNPs in the KCNJ11-ABCC8 gene locus are associated with type 2 diabetes and blood pressure levels in the Japanese population. J Hum Genet 2007, 52:781-793.
65. Florez J.C., Burtt N., de Bakker P.I.W., et al. Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes 2004, 53:1360-1368.
66. Famulla S., Lamers D., Hartwig S., et al. Pigment epithelium-derived factor (PEDF) is one of the most abundant proteins secreted by human adipocytes and induces insulin resistance and inflammatory signaling in muscle and fat cells. Diabetes 2010, 59:A98.
67. Chung C., Doll J.A., Gattu A.K., et al. Anti-angiogenic pigment epithelium-derived factor regulates hepatocyte triglyceride content through adipose triglyceride lipase (ATGL). J Hepatol 2008, 48:471-478.
68. Nakamura K., Yamagishi S., Adachi H., et al. Serum levels of pigment epithelium-derived factor (PEDF) are positively associated with visceral adiposity in Japanese patients with type 2 diabetes. Diabetes Metab Res Rev 2009, 25:52-56.
69. Wang P., Smit E., Brouwers M.C., et al. Plasma pigment epithelium-derived factor is positively associated with obesity in Caucasian subjects, in particular with the visceral fat depot. Eur J Endocrinol 2008, 159:713-718.
70. Sutton B.S., Weinert S., Langefeld C.D., et al. Genetic analysis of adiponectin and obesity in Hispanic families: the IRAS Family Study. Hum Genet 2005, 117:107-118.
71. Spitz M.R., Detry M.A., Pillow P., et al. Variant alleles of the D2 dopamine receptor gene and obesity. Nutr Res 2000, 20:371-380.